Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.
Also called NCT04142125
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 101 participants
- Registry
-
NCT04142125
-
- Other papers using this trial's data
- Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT04142125. Randomized; single masking; primary purpose treatment. Start 2020-02-03 (actual); primary completion 2023-09-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease
- Condition
- Ischemic Stroke
- Condition
- Intracranial Atherosclerotic Disease
- Intervention (Drug)
- Rivaroxaban 2.5 Mg Oral Tablet bid
- Intervention (Drug)
- Acetylsalicyclic acid 81 mg tablet qd
- Lead sponsor
- Population Health Research Institute
Record details
- Record id
cardio:ct-nct04142125- Content hash
c032eb137b33793be9306b06e71ae7a785f69da06e5ac0e60ff9da08d1327509